文献速递心外重症与机械循环支持先天性心脏病外科

第三届儿科机构间机械循环支持注册(Pedimacs)报告:植入前特征与结局

Third Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report: Preimplant Characteristics and Outcomes.
PubMed 文献 · Ann Thorac Surg · 2019-02-26

Pedimacs登记2012年9月至2017年12月30家医院423例<19岁患者的508台VAD,心肌病占62%、先天性心脏病(CHD)占20%。6个月正面结局80%,死亡20%;植入式连续流(IC)泵6个月正面结局92%,优于搏动式(PP)77%和体外连续流(PC)63%。

要点

  • IC泵是儿童最常用VAD类型,6个月正面结局超90%
  • PP/PC泵主要用于体重<20 kg或CHD等更复杂患者
  • 植入时Intermacs 1级、双心室辅助等与早期死亡风险相关

核心结论

  • IC VAD在儿童中6个月正面结局超过90%,可能反映患者选择与植入时机成熟。
  • PP/PC装置目前限于支持体重<20 kg和CHD等最具挑战的患者。

研究设计与样本

  • Pedimacs为美国国立卫生研究院资助的登记数据库,2012年9月19日至2017年12月31日30家医院植入508台装置于423例<19岁患者。
  • 本报告因管理权移交胸外科医师学会,未纳入2018年8月1日前未签约机构的数据。

主要发现

  • 423例中诊断心肌病261例(62%)、心肌炎48例(11%)、其他28例(7%)、CHD 86例(20%),其中52例为单心室生理。
  • 支持策略以左心室辅助342例(81%)和双心室辅助64例(15%)最常见。
  • 6个月正面结局(存活带装置或桥接移植/恢复)为80%,总死亡率20%。
  • IC泵队列(n=197;植入年龄13.4±3.8岁;19% Intermacs 1级、21%插管、12% CHD)与PC泵(n=79;年龄3.9±5.2岁;49% Intermacs 1级、86%插管、38% CHD)和PP泵(n=121;年龄3.3±3.9岁;41% Intermacs 1级、77%插管、21% CHD)显著不同。
  • 6个月正面结局:PC 63%、PP 77%、IC 92%。

关键数值与推荐

  • 参数风险模型显示早期死亡风险与Intermacs 1级、双心室辅助、经皮装置、PC装置、小容量机构、低年龄和低体重相关。
  • 恒定风险与植入时插管和肝功能障碍相关。

临床怎么用

  • 儿童VAD选择可参考装置类型与患者特征匹配:IC泵用于条件较好者,PP/PC用于体重<20 kg或CHD等复杂患者。
  • 植入时需关注Intermacs分级、插管状态、肝功能障碍及机构容量等风险因素。

局限性

  • 本报告未纳入2018年8月1日前未签约机构的数据,可能影响代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The influence of ventricular assist device (VAD) use in the care of children with end-stage heart failure is growing rapidly through increasing numbers, new devices, expanding indications, and improving outcomes. Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs), a National Institutes of Health-sponsored United States database, provides a platform to understand this emerging population. METHODS: Between September 19, 2012, and December 31, 2017, 30 hospitals implanted 508 devices in 423 patients aged younger than 19 years. This past year was one of evolution for the database as its management was transitioned to The Society of Thoracic Surgery; therefore, this report does not include data from institutions not under contract by August 1, 2018. RESULTS: Of the 423 patients, the diagnosis was cardiomyopathy in 261 (62%), myocarditis in 48 (11%), other in 28 (7%), and congenital heart disease (CHD) in 86 (20%), with 52 of these patients having single-ventricle physiology. The two most common support strategies included left VAD in 342 (81%) and biventricular assist device in 64 (15%). Positive outcome (alive on device or bridge to transplantation/recovery) was 80% at 6 months (overall mortality of 20%). The patient cohort for implantable continuous-flow (IC) pumps (n = 197; age at implant, 13.4 ± 3.8 years; 19% Interagency Registry for Mechanically Assisted Circulatory Support [Intermacs] profile 1, 21% intubated at implant, and 12% with CHD) was significantly different from the paracorporeal continuous-flow (PC) pump cohort (n = 79; age, 3.9 ± 5.2 years; 49% Intermacs profile 1, 86% intubated at implant, and 38% with CHD) and the paracorporeal pulsatile (PP) pump cohort (n = 121; age, 3.3 ± 3.9 years; 41% Intermacs profile 1, 77% intubated at implant, and 21% with CHD). Consistent with their cohort composition, device type positive outcomes at 6 months were PC, 63%; PP, 77%; and IC, 92%. Parametric hazard modeling showed an early hazard for death was associated with Intermacs profile 1, biventricular assist device, percutaneous devices, PC devices, small-volume institutions, low age, and low weight, whereas a constant hazard was associated with intubation and liver dysfunction at time of implant. CONCLUSIONS: IC VADs are the most common VAD type placed in children. The positive outcomes for the IC VADs exceed 90% at 6 months, which may represent our field's maturation in both patient selection and timing of implantation. The PP/PC devices are currently limited to supporting our most challenging patients, those weighing less than 20 kg and those with CHD. The introduction of new devices and our communities' commitment to shared learning and improvement will lead to more pediatric lives saved by VAD support and will also focus on improving the quality of life of children supported with VADs.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Morales DLS, Rossano JW, VanderPluym C, et al. Third Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report: Preimplant Characteristics and Outcomes. Ann Thorac Surg. 2019. PMID: 30817920. doi:10.1016/j.athoracsur.2019.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。